Novelix Pharmaceuticals Ltd

📊 Novelix Pharmaceuticals Revises Q3 FY2025 Results After Typo Correction

- Total income for Q3 (ended Dec 31, 2025): ₹4,840.27 lakhs

- Net profit after tax: ₹100.44 lakhs

- Earnings per share (EPS): basic ₹0.58 and diluted ₹0.85 for continuing operations

- Revised results approved by the Board of Directors on February 12, 2026

- Company operates solely in pharmaceutical research, manufacturing, and trading